Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle

Diabetes

Volumn 51, Issue 10, 2002, Pages 3025-3032

  Anderwald, Christian ^a   Bernroider, Elisabeth ^a   Krššák, Martin ^a   Stingl, Harald ^a   Brehm, Attila ^a   Bischof, Martin G ^a   Nowotny, Peter ^a   Roden, Michael ^a   Waldhäusl, Werner ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; NEUTRAL INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INFUSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID LIVER LEVEL; MALE; MUSCLE LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SKELETAL MUSCLE; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE;

EID: 0036788388     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.10.3025     Document Type: Article

References (49)

1. Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. DeFronzo RA: Lilly Lecture 1987: the triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
3. Bergman RN: Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43:946-952, 2000
4. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84:1513-1517, 1999
5. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758, 2000
6. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850, 2001
7. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2865, 1996
8. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259, 1999
9. Brechtel K, Dahl DB, Machann J, Bachmann OP, Wenzel I, Maier T, Claussen CD, Häring HU, Jacob S, Schick F: Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia: a dynamic 1H-MRS study. Magn Reson Med 45:179-183, 2001
10. Boden G, Lebed B, Schatz M, Homko C, Lemieux S: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612-1617, 2001
11. Krebs M, Krššák M, Nowotny P, Weghuber D, Gruber S, Mlynarik V, Bischof M, Stingl H, Fürnsinn C, Waldhäusl W, Roden M: Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 86:2153-2160, 2001
12. Krššák M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:113-116, 1999
13. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600-1606, 1999
14. Virkamäki A, Korsheninnikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Hakkinen AM, Yki-Järvinen H: Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50:2337-2343, 2001
15. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Häring HU: Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48:1113-1119, 1999
16. Roden M, Krššák M, Stingl H, Gruber S, Hofer A, Fürnsinn C, Moser E, Waldhäusl W: Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes 48:358-364, 1999
17. Kelley DE, Goodpaster BH: Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care 24:933-941, 2001
18. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320, 2000
19. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G: Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EG1R). J Clin Invest 100:1166-1173, 1997
20. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477-490, 1998
21. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
22. Hidaka H, Nagulesparan M, Klimes I, Clark R, Sasaki H, Aronoff SL, Vasquez B, Rubenstein AH, Unger RH: Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J Clin Endocrinol Metab 54:217-222, 1982
23. Firth RG, Bell PM, Rizza RA: Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 314:1280-1286, 1986
24. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
25. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, Couper JJ, Tait BD, Colman PG, Harrison LC: Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 49:1319-1324, 2000
26. Hother-Nielsen O, Henriksen JE, Holst JJ, Beck-Nielsen H: Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 45:82-91, 1996
27. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R: Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 9:79-93, 1989
28. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
29. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223, 1979
30. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33:634-642, 1984
31. DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23:313-319, 1982
32. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D: Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238-1246, 1984
33. Wise SD, Nielsen MF, Cryer PE, Rizza RA: Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:2461-2469, 1998
34. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quinones-Galvan A, Sironi AM, Natali A, Ferrannini E: Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50:1807-1812, 2001
35. Ruddock M, Landaker E, Park J, Stein A, Patti ME: Free fatty acids inhibit insulin action by modulating insulin receptor expression and post-receptor signaling via β-oxidation-dependent mechanisms (Abstract). Diabetes 49 (Suppl. 1):A51, 2000
36. Williamson JR, Kreisberg RA, Felts PW: Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A 56:247-254, 1966
37. Stingl H, Krššák M, Krebs M, Bischof MG, Nowotny P, Fürnsinn C, Shulman GI, Waldhäusl W, Roden M: Lipid-dependent control of hepatic glycogen stores in healthy humans. Diabetologia 44:48-54, 2001
38. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhäusl W, Shulman GI: Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707, 2000
39. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG: Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 41:1400-1408, 1992
40. Bischof MG, Krššák M, Krebs M, Bernroider E, Stingl H, Waldhäusl W, Roden M: Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes 50:392-398, 2001
41. Waldhäusl WK, Bratusch-Marrain PR, Francesconi M, Nowotny P, Kiss A: Insulin production rate in normal man as an estimate for calibration of continuous intravenous insulin infusion in insulin-dependent diabetic patients. Diabetes Care 5:18-24, 1982
42. Fasching P, Ratheiser K, Damjancic P, Schneider B, Nowotny P, Vierhapper H, Waldhäusl W: Both acute and chronic near-normoglycaemia are required to improve insulin resistance in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:346-351, 1993
43. Kelley DE, Goodpaster B, Wing RR, Simoneau JA: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 277:E1130-E1141, 1999
44. Blaak EE, Wagenmakers AJ, Glatz JF, Wolffenbuttel BH, Kemerink GJ, Langenberg CJ, Heidendal GA, Saris WH: Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab 279:146-154, 2000
45. Blaak EE, Aggel-Leijssen DP, Wagenmakers AJ, Saris WH, van Baak MA: Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes 49:2102-2107, 2000
46. Dyck DJ, Steinberg G, Bonen A: Insulin increases FA uptake and esterification but reduces lipid utilization in isolated contracting muscle. Am J Physiol Endocrinol Metab 281:E600-E607, 2001
47. Mathoo JM, Shi ZQ, Klip A, Vranic M: Opposite effects of acute hypoglycemia and acute hyperglycemia on glucose transport and glucose transporters in perfused rat skeletal muscle. Diabetes 48:1281-1288, 1999
48. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 47:677-683, 2000
49. Assimacopoulos-Jeannet F, Brichard S, Rencurel F, Cusin I, Jeanrenaud B: In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues. Metabolism 44:228-233, 1995